Helen Obaro

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease”.

Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease

EBioMedicine(2021)10.1016/j.ebiom.2021.103380

N/A

1.2DataRank · unranked

58 citations

Krista L. Namminga, Yaman Lu, Aaron Schwab, Mackenzie J. Thurston, Mai Mohamed Abdelmoaty +7 more

An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

Translational Neurodegeneration(2023)10.1186/s40035-023-00361-1

N/A

0.759DataRank · unranked

33 citations

Mai Mohamed Abdelmoaty, Krista L. Namminga, Yaman Lu, Helen Obaro, Pamela M. Santamaria +3 more

A multiyear follow-on study examining safety, immunity, and clinical outcomesfor sargramostim therapy in Parkinson’s disease

Research Square(2022)10.21203/rs.3.rs-1957469/v1

N/A

0DataRank · unranked

0 citations

Katherine E. Olson, Krista L. Namminga, Yaman Lu, Mai Mostafa, Helen Obaro +3 more